



MAXPOTENT PHARMA SUMMIT 2025

DRIVING EXCELLENCE
IN POTENT DRUG
DEVELOPMENT



25-26
September
2025

Duo Milan
Porta Nuova,
Milan, Italy

— POST EVENT — REPORT

For more information, contact akshita@convolign.com

— CONCEPTUALIZED BY —

 **convolign**

SYNOPSIS – MAXPOTENT PHARMA SUMMIT

The **MaxPotent Pharma Summit** provided an authoritative platform for professionals across the pharmaceutical and biopharma sectors to explore the latest trends, challenges, and innovations in **High-Potency Active Pharmaceutical Ingredients (HPAPIs)**. The summit convened regulatory experts, pharmaceutical innovators, and contract manufacturing organizations (CMOs/CDMOs) to discuss critical topics including **regulatory compliance, containment technologies, process optimization, risk mitigation, and occupational safety**. Participants engaged in in-depth sessions covering emerging best practices, technological advancements, and strategies for navigating the complex

HPAPI landscape. Beyond knowledge-sharing, the event offered robust **networking opportunities**, enabling stakeholders to forge collaborations, exchange ideas, and explore potential partnerships. With insights into market dynamics, operational efficiencies, and safety considerations, the summit empowered attendees with actionable guidance to enhance manufacturing processes, ensure regulatory adherence, and drive innovation in high-potency drug development. Overall, the event successfully combined thought leadership, technical expertise, and interactive discussions to create a highly impactful experience for all participants.



Key Focus Areas & Highlights:



Regulatory Compliance:

Updates and insights into navigating HPAPI-specific regulations and global standards.



Containment Technologies:

Latest innovations to ensure safe handling of high-potency compounds.



Process Optimization:

Best practices for efficient, scalable, and risk-controlled manufacturing.



Risk Mitigation & Safety:

Strategies for minimizing exposure, ensuring worker safety, and maintaining environmental compliance.



Networking &

Collaboration: Opportunities to build partnerships and foster knowledge exchange among pharma innovators, CMOs/CDMOs, and regulatory experts.



Market Insights:

Understanding trends in HPAPI demand, technology adoption, and growth projections.



CDMO Insights:

- Strategies for CMOs/CDMOs to enhance operational efficiency and maintain compliance in HPAPI production.
- Opportunities for contract manufacturers to expand service offerings, adopt advanced containment solutions, and collaborate with pharma innovators.



Thought Leadership:

Keynote sessions and panel discussions featuring industry leaders and subject-matter experts.



Maxpotent Pharma Summit Speaks on



Regulatory

- Navigating global HPAPI regulations and standards
- Regulatory requirements for containment and exposure limits
- Compliance strategies for multi-jurisdictional HPAPI manufacturing
- Documentation, auditing, and quality assurance in HPAPI processes



Manufacturing

- High-potency process design and scale-up strategies
- Advanced containment technologies for production and packaging
- Automation and robotics in HPAPI handling
- Technology transfer and process optimization for CDMOs
- Cleaning and validation of HPAPI equipment and facilities
- Analytical methods for monitoring contamination and ensuring product quality



Safety

- Occupational exposure control and risk assessment
- Personal protective equipment (PPE) advancements
- Waste management and environmental compliance for potent compounds
- Emergency response planning for HPAPI incidents
- Cleaning and validation to prevent cross-contamination and ensure safety



CDMO + Pharma Partnerships

- Strategies for CDMOs to enhance operational efficiency and compliance
- Service expansion and adopting advanced containment solutions
- Best practices in contract manufacturing for HPAPI clients
- Building strategic collaborations between pharma companies and CDMOs
- Joint development programs for novel high-potency drugs
- Networking opportunities to explore partnerships and co-development projects



Key Highlights 2025



**Cleaning validation for HPAPI
– One driver to prevent
cross-contamination**

Andreas Schreiner, Global
Validation Leader, **Novartis**



**High Containment
HPAPI Kilo Lab & Production
Development Scale Plant**

Andrew Lemaire, Technical Director
of Containment & Micronization
Technologies, **DEC Group**



**Toxicology Aspects in Worker
and Patient Safety**

Martin Kohan, Managing
Toxicologist,
SafeBridge Europe, UK



**Advanced HPAPI containment
systems:** engineered to handle
CPTs down to 1 ng-

Stefano Butti, Technical Sales
Director, **FPS Pharma**



**From Compliance to Competitive
Advantage:** Embedding Sustainability
Across the Pharma Value Chain

Matteo Alaria, Senior Sustainability
Leader – Former Head of
Sustainability, **Sartorius**



**High Containment Hpapi Kilo
Lab & Production Development
Scale Plant**

David Cragin, Senior Director, Occ
& Env Hlth Sciences, Environment,
Health, Safety and Sustainability,
Teva Pharmaceuticals



**Understanding European
Regulatory Requirements for
High-Containment Facilities**

Giorgio Mari, Senior Process
Engineer, **Exyte**



**Pre-reconstruction risk evaluation for a
development API plant – a cross
contamination/containment assessment**

Ildikó Dr. Ziegler, Director of Quality,
Hunazine Biotech S.L.





Who attended?

From Pharmaceutical, Biopharmaceutical, and Contract Manufacturing:

Senior Managers, Principal Scientists,
Principal Toxicologists, Fellows, Investigators
Chief Executives, Vice Presidents, Directors,
Heads, Leaders

Key Departments:

- Validation
- Manufacturing/Operations/Production
- Occupational Toxicology
- Process Development/Technical Transfer
- Environmental, Health & Safety (HSE)
- Risk Assessments
- Product Quality
- Engineering
- Regulatory Affairs
- Formulation Development
- New Products
- Research & Development
- Industrial Hygiene
- Laboratory Services/Analytical
- New Technologies
- Maintenance



Speakers & Advisors 2025



Dean Calhoun
CEO
Affygility Solutions, USA



Andrew Lemaire
Technical Director of Containment
& Micronization Technologies
DEC Poland Tekpro Sp. z o.o.



Stefano Butti
Technical Sales Director
FPS Pharma



Fabio Zenobi
EHS Director
BSP Pharmaceuticals S.p.A.



Roberto Furlan
Sales Manager
CSV



Andrea Weiss
International Business Strategist
AM Instruments



William Hawkins
Senior Managing Toxicologist
SafeBridge Europe, Ltd



Justin Mason-Home
Director
HPAPI Project Services, UK



Martin Kohan
Managing Toxicologist
SafeBridge Europe, UK



Jack Brown
Senior Principal Scientist
Boehringer Ingelheim



Richard Hall Hall
Mechanical Engineer
RATTINOX S.R.L.



Andreas Schreiner
Global Validation Leader
Novartis





Mahfoud Zerarka

Procurement Manager

Sanofi



Dr. Ildikó Ziegler

Director of Quality

Hunazine Biotech



David Cragin

Senior Director, Occ & Env Hlth
Sciences, Environment, Health,
Safety and Sustainability

Teva Pharmaceuticals



Giorgio Mari

Senior Process Engineer

Exyte



Jihene Elkhail

Validation Lead

Octapharma



Matteo Alaria

Senior Sustainability Leader –
Former Head of Sustainability



Gastón Ariel Estruch

Technical Director en GENTEC
Pharmaceutical Group

Pharmanoid Site



Angéline MPEMBA BONI

Stability Specialist

Bristol Myers Squibb



Sponsors & Partners 2025



Companies Participated 2025

- Minakem
- Olon S.p.A
- Dipharma Francis Srl
- TEVA – TAPI
- AM Instruments
- Novartis
- Dec Group
- Genmab
- Abbvie
- Bristol Myers Squibb
- Zeotis
- Kikusui Europe
- Novo Nordisk
- Indena
- Icom
- Teva Pharmaceuticals
- Thermo Fisher Scientific
- BSP Pharmaceuticals
- Affigility Solutions, USA
- Hunazine Biotech
- Takeda
- Evonik
- Esteve Quimica
- FPS Pharma
- Quascenta | PQMS
- Watson Marlow Fluid Technology Solutions
- Morpho by Alfasigma
- Gentec Pharmaceutical Group, Pharmanoid Site
- GSK
- Gilead
- Pfizer
- Exyte
- Adare Pharma Solutions
- Ferrero
- Boehringer Ingelheim
- Roche
- Octapharma
- HPAPI Project Services, UK
- CSV Containment
- Sanofi
- Wuxi STA
- SafeBridge Europe
- Inke
- Sartorius
- CTS Europe
- AstraZeneca
- Bayer
- Howarth Air Tech
- Rattinox Srl
- Fareva
- UCB Pharma
- Accord Healthcare
- Pharmanoid
- Eli Lilly



Sponsor Testimonials:

The event was exceptionally well organized, offering ample networking opportunities with a large number of attendees and presenters. The hospitality was excellent, and it was a pleasure to interact with colleagues while highlighting the importance of toxicology in areas such as containment, risk assessment, and both worker and patient protection. We look forward to collaborating with Convolign on future events as well.



Martin Kohan, Managing Toxicologist, **Safebridge Europe, UK**

We truly felt we were at the right place. Over the past two days, we had insightful discussions around containment systems. The event brought together many customers, key manufacturers, and leading engineering companies, making it a great platform to exchange knowledge, information, and experience. We will definitely look forward to joining next year's edition.



Stefano Butti, Technical Sales Director, **FPS Pharma & Food Systems Srl**

I found the event very engaging, with a wide range of interesting topics covered. The venue was excellent, offering plenty of opportunities for networking, and the hospitality was truly remarkable.



Andrea Weiss, International Business Strategist, **AM Instruments**

Congratulations to the entire team of Convolign Business Consulting for organising such a wonderful event. It was a perfect platform to gain insights into the key factors and technologies shaping high potent drug manufacturing. We also had excellent opportunities to network with peers and connect with new clients.



Andrea Confetti, Chairman, **Dipharma Francis Srl**

The event was highly informative, and we made some excellent industry contacts to introduce our systems to. The footfall was impressive, and the presentations were insightful. Overall, it was a great event for us, and we look forward to attending the next edition.



Mike Shemeld, Technical Sales Manager, **CTS Europe**

We had an excellent delegate turnout. The one-to-one meetings were very well organised and provided a great platform to connect with leaders from across various segments of HPAPI drug development. Truly a valuable opportunity for meaningful discussions and collaborations.



Roberto Furlan, Sales Manager, **CSV Containment**

Extremely thankful to the entire team of Convolign Business Consulting for organising the MaxPotent Pharma Summit 2025. The event was a perfect platform to introduce both myself and my company to the high potent drug manufacturing field, while also connecting with key leaders and experts from the industry.



Fabio Zenobi, EHS Director, **BSP Pharmaceuticals**

The event was highly informative, and the topics shared by the speakers were both interesting and highly relevant to us. We thoroughly enjoyed being part of the two-day event.



Stephen Carpmail, Global Sales Manager, **DEC Group**

It was a very good experience with excellent attendee participation. The topics covered were highly relevant and interesting. We will definitely look forward to attending the event again next year.



Marziale Comito, Business Development Manager, **Morpho by Alfasigma**

The event was very interesting and successful, bringing together key decision-makers from the industry. The sessions covered important topics such as high containment designs, digitalisation & digital transformation, and sustainability. We are definitely looking forward to joining the event in 2026.



Daniele Oldani, Business Development Manager, **Icrom Srl**



Captured Moments

Maxpotent Pharma Summit 2025



Captured Moments

Maxpotent Pharma Summit 2025



How To Participate

join as

SPEAKER/ADVISOR/PANEL MODERATOR/PANELIST



Madhumati Patil

Production Manager

madhumati@convolign.com

+91-98608 51975

join as

SPONSOR/EXHIBITOR



Akshita Lohia

Sponsorship Manager

akshita@convolign.com

+91 70162 80834

join as

DELEGATE/ATTENDEE



Akshita Lohia

Sponsorship Manager

akshita@convolign.com

+91 70162 80834





THANK YOU!

For more information, contact
akshita@convolign.com

www.maxpotentpharmasummit.com

— CONCEPTUALIZED BY —
 **convolign**

MaxPotent Pharma Summit 2025